In breast cancer radiation has a central role in the treatment of brain metastasis, even though tumor sensitivity might be limited. The tumor cell defense response to ionizing radiation involves activation of cell cycle checkpoint signaling. Histone deacetylase (HDAC) inhibitors, agents that cause hyperacetylation of histone proteins and thereby aberrations in the chromatin structure, may also override the DNA damage defense response and facilitate the radiation-induced mitotic cell death. In experimental metastasis models, the human breast carcinoma cell line MA-11 invariably disseminates to the central nervous system. We compared in vitro MA-11 cell cycle response profiles to ionizing radiation and HDAC inhibition. After radiation exposure the G 2 /M phase accumulation and the preceding repression of the G 2 phase regulatory factors Polo-like kinase-1 and cyclin B1 required intact G 2 checkpoint signaling through the checkpoint kinase CHK1, whereas the similar phenotypic changes observed upon HDAC inhibition did not. The MA-11 cells did not show radiationinduced expression of the G 1 cell cycle inhibitor p21, indicative of a defective G 1 checkpoint and consistent with a point mutation detected in the tumor-suppressor TP53 gene. Increase in the p21 level, however, was observed upon HDAC inhibition.
Introduction
In breast cancer radiation as therapeutic modality has clearly documented palliation effect on advanced metastatic disease in the brain or meninges. Within this patient population, however, survival may vary from a few months to a couple of years.
Hence, improvement of the standard therapy might potentially benefit many patients (1) .
We have previously characterized the MA-11 human breast carcinoma cell line for its ability to form experimental organ-specific metastases in vivo. This cell line was established from micrometastatic cells enriched from a bone marrow sample taken from a patient who was clinically devoid of metastatic disease (2) , but was somewhat unexpectedly found to form metastases within the central nervous system after systemic injection in rodents (2) (3) (4) . This experimental metastasis model has been characterized for therapeutic responses to a variety of pharmacological compounds with cytotoxic activity (3, 5) .
Cell cycle checkpoints constitute regulatory mechanisms that do not allow the initiation of a new phase of the cell cycle to proceed before the previous one is completed (6) . The tumor cell response to DNA damage involves a temporary cell cycle delay at the G 1 /S or G 2 /M boundaries, each based on unique mechanisms, to activate a cascade of responses to the damage, ultimately leading to the outcome of cell survival if the DNA is properly repaired, or, if not, to apoptotic or mitotic cell death (7) .
The tumor-suppressor protein p53 is the primary regulator of the G 1 checkpoint (7) . Essentially, in tumor cells with intact p53 function, DNA damage leads to rapid p53 stabilization by post-translational protein modifications as well as induction in the level of the G 1 phase inhibitor p21 (7) .
In the orderly dividing cell the transition from the G 2 phase to mitosis is inhibited through phosphorylations of the Cdc2 kinase of the Cdc2/cyclin B complex.
Upon the onset of mitosis these inhibitory phosphorylations are removed by the Cdc25C phosphatase. The activation of Cdc25C requires positive regulatory phosphorylation, accomplished by the Polo-like kinase-1 (Plk1) (8) . DNA damageinduced G 2 checkpoint signaling, initiated by the ATM kinase and communicated through downstream mediator proteins like p53 and the checkpoint kinase CHK1 (6, 9) , will ultimately disrupt the interaction of Cdc25C with Cdc2 (6) . We have previously found that the mechanism of the G 2 phase response to ionizing radiation comprises repression of the genes for Plk1 and cyclin B1, PLK and CCNB1 (10).
Molecular targeted agents can have direct effects on the cellular response pathways implicated upon exposure to ionizing radiation (11) . A variety of pharmacological compounds, designed to target cell cycle regulatory mechanisms, have been shown to override the DNA damage defense response that prevents mitotic entry (9, 11) . Hence, such agents may have a therapeutic potential as radiosensitizers by facilitating mitotic cell death, and several are currently tested in early-phase clinical trials. We have recently reported that pharmacological inhibition of the CHK1 kinase counteracted the tumor cell defense responses on PLK and CCNB1, and thereby the G 2 arrest, following radiation exposure (10, 12) . In agreement with this, the concomitant treatment with the CHK1 inhibitor seemed to amplify the cytotoxic effect of ionizing radiation on clonogenic regrowth (12) .
Drugs that modify the cellular chromatin structure may also radiosensitize tumor cells. Taxanes, which disrupt chromatin structure and chromosome segregation in mitotis, are currently utilized clinically as radiosensitizers in treatment of non-small cell lung cancer and head-and-neck cancer (13) . Cellular treatment with histone deacetylase (HDAC) inhibitors causes hyperacetylation of histone proteins, which leads to aberration in the chromatin structure (14) . In addition to this, the pertubation by HDAC inhibitors of cell cycle checkpoint signaling (15) , might constitute the cellular mechanism by which these compounds enhance tumor cell sensitivity to radiation treatment.
Currently several HDAC inhibitors are undergoing early-phase clinical investigation (14) . Such pipeline drugs are not easily accessible, and in this report we have used a commercially available HDAC inhibitor, trichostatin A (TSA). TSA has shown excessive toxicity under in vivo conditions, and in this study we have therefore compared the biological mechanisms involved in the responses of the MA-11 cell cycle phenotype after exposure to TSA and ionizing radiation in cultured cells. A reduction in MA-11 clonogenic regrowth by the concomitant treatment with TSA and radiation is further indicated.
Materials and Methods

Cell Lines and Experimental Treatments
The human carcinoma cell lines MA-11 and MT-1 were cultured as previously described (4). High-energy radiation from a 60 Co source was delivered at a rate of approximately 1 Gy/min. The unirradiated control cells were simultaneously placed in room temperature to obtain exactly comparable conditions. The commercially available HDAC inhibitor TSA (Sigma-Aldrich Norway, Oslo, Norway) was added to the media in final concentrations of 10-300 nM. In experiments using the selective CHK1 kinase inhibitor UCN-01 (National Cancer Institute, Bethesda, MD), this compound was added in a final concentration of 100 nM to the cell media, as recommended by the supplier, 15 minutes before irradiation or TSA treatment.
Western Blot Analysis
Protein expression was measured by means of standard Western blot technique, essentially as previously described (10 anti-Plk1 (Zymed; 33-1700), and anti-p21 (SC-6246), respectively.
Flow Cytometry Analysis
The MA-11 cells were harvested in ice-cold PBS, and after centrifugation the cell pellets were fixed in 100% methanol. To determine the fractions of cells in the G 1 , S, and G 2 /M phases from the cell cycle distribution, the cells were stained with 1.5 µg/ml Hoechst 33258 in PBS and analyzed in a FACStar+ flow cytometer (Becton Dickinson, San Jose, CA), as described previously (10) .
Mutation Analysis of the TP53 Gene
DNA extracted from the cell lines was analyzed for possible TP53 mutations using the method of constant denaturant gel electrophoresis (CDGE) (16) . The screening was performed using PCR to amplify exons 2, 3, and 6−11 individually, as well as the large exons 4 and 5 each as two sequential PCR products (17) . The sample that showed aberrantly migrating bands, indicating mutation, was reamplified using the original set of primers, of which one was biotinylated, and the same thermal cycling condition. The biotinylated PCR product was sequenced directly by means of
The results from the clonogenic regrowth measurements were analyzed using the combination index (CI) method of Chou and Talalay (18) . 
Results
HDAC Inhibition -Histone Acetylation and PARP Protein Status
Tumor cell sensitivity to pharmacological HDAC inhibition may vary along a wide concentration range and should be considered highly cell line specific. Thus, the initial experiment was performed to determine the effect of increasing concentrations of TSA (10-300 nM) on the histone acetylation status of the MA-11 cell line. As seen 
Ionizing Radiation and HDAC Inhibition -Redistribution of Cell Cycle Phases
Pharmacological inhibition of HDAC activity has been shown to cause cell cycle arrest at the G 2 /M boundary in a variety of tumor cell lines (19, 20, (22) (23) (24) , resembling the G 2 checkpoint response to DNA damage induced by ionizing radiation (10, 12, 25) . Hence, the MA-11 cells were exposed to a radiation dose of 8.0 Gy or 300 nM TSA, and cell cycle profiles were followed for 24 hours ( 
p53 Status
In the MA-11 cells a distinct G 1 phase was detected following both irradiation and TSA treatment (Fig. 2) . The persisting G 1 phase cells may reflect an incomplete Furthermore, both cell lines showed essentially equal levels of mRNA expression for TP53 (Fig. 3, middle panel) . However, whereas strong p53 protein expression was found in the MA-11 cell line, in accordance with the intense nuclear staining of p53 previously detected by immunocytochemistry (2), p53 expression was almost undetectable in the MT-1 cell extracts. A weak band representing the p53 protein was seen after long-term exposure of the immunoblot (Fig. 3, lower panel) .
Primarily, p53 stabilization results from disruption of the interaction between p53 and the MDM2 oncoprotein, which thereby protects p53 from ubiquitin-mediated degradation (26) . Whereas expression of two major MDM2 polypeptides was observed in the MT-1 cells, MDM2 was almost undetectable in the MA-11 cells (Fig.   3 , lower panel).
Ionizing Radiation and HDAC Inhibition -Responses of Cell Cycle
Regulatory Proteins
The responses of regulatory proteins of the G 1 and G 2 cell cycle phases were followed for 24 hours after MA-11 cell exposure to ionizing radiation (8.0 Gy) or TSA (300 nM). As seen from Fig. 4 , expression of the G 2 phase kinase Plk1 was found to be down-regulated 6 hours after irradiation, with an apparent increase above the control Plk1 level, probably compensatory, after12−24 hours. This has also been observed in irradiated MT-1 cells (12) . A transient Plk1 repression was also seen 6−12 hours after start of the TSA treatment but almost recovered after 24 hours. From below detection, the level of the G 1 phase inhibitor p21 was induced 12 hours after addition of TSA and further observed as clearly accumulating after 24 hours.
Coincident with this, the high level of p53 was significantly repressed. In contrast to the TSA-dependent effects on p21 and p53, the expression levels of these proteins
were not altered by radiation.
The regulatory responses on cell cycle proteins seemed to reflect changes in mRNA levels after exposure of the MA-11 cells to ionizing radiation or TSA (Fig. 5) .
As previously observed in other breast cancer cell lines (10, 12, 25) , the level of PLK mRNA (encoding Plk1) was barely detectable 6 hours after irradiation but almost recovered after 12 hours, and the response of CCNB1 mRNA (encoding the G 2 phasespecific cyclin B1) was essentially identical. The transient down-regulation of these mRNAs by TSA was observed for some longer period (6−12 hours) before their expression again was up-regulated 24 hours after start of the TSA treatment. The mRNA expression of CDKN1A (encoding p21) was not altered after irradiation, which is highly indicative of a defective G 1 checkpoint (7). In the presence of TSA, however, expression of CDKN1A mRNA was inversely reflecting the regulatory effects on the mRNAs for PLK and CCNB1.
Ionizing Radiation and HDAC Inhibition -Regulatory Role of CHK1
We have recently shown that the cell cycle phenotype responses following radiation-induced DNA damage require intact G 2 checkpoint signaling through the downstream checkpoint kinase CHK1 (10, 12) . In accordance with this, treatment with the CHK1 inhibitor UCN-01 (100 nM) also seemed to counteract the G 2 /M phase arrest observed 12−24 hours after exposure of the MA-11 cells to a radiation dose of 8.0 Gy, but not upon incubation with TSA (300 nM) for 24 hours, as seen by comparing the histograms displayed by the upper and lower panels of Fig. 2 .
Furthermore, whereas the suppressed mRNA levels of PLK and CCNB1 following irradiation of the MA-11 cells were entirely abolished by UCN-01, the regulatory effects of TSA on those mRNAs, and on CDKN1A mRNA, were not (Fig. 5) . Hence, our data strongly indicate that the effector mechanisms of the G 2 phase responses to ionizing radiation and HDAC inhibition are mediated via distinct regulatory pathways.
Ionizing Radiation and HDAC Inhibition -Clonogenic Regrowth
Finally, the MA-11 cell line was exposed to increasing doses of ionizing radiation to determine clonogenic survival (Fig. 6 ). The cell line showed nearly exponential loss of colony formation efficiency, with a surviving fraction of ~0.01
with the highest radiation dose applied (10 Gy).
Since the regulatory pathway recruited by HDAC inhibition seemed to be distinctly different from that following irradiation, the possible radiosensitizing effect of TSA, essentially by amplifying the cytotoxic effect of ionizing radiation on clonogenic regrowth, was measured. Based on the histone acetylation data (Fig. 1,   upper panel) , we chose to analyze MA-11 cells treated with TSA (10-300 nM) for 12 hours before the HDAC inhibitor was removed and the cells irradiated. This treatment strategy was supported by the observations that irradiation followed by the immediate TSA treatment for 12 hours did not reduce MA-11 cell clonogenicity compared to irradiation alone and that TSA incubations for 24 hours or more before or after radiation exposure turned out to induce complete cytotoxicity in this cell line (results not shown).
The effects of the TSA pretreatment on several radiation doses were measured (Fig. 6 ) and analyzed by means of the CI method (Table 1 ). In most of the dose range analyzed (0.50-5.0 Gy) the ability of clonogenic regrowth of irradiated MA-11 cells was reduced by a factor of ≤3 after pretreatment with 300 nM TSA. The cytotoxic effect of 8.0 Gy of ionizing radiation on clonogenicity (surviving fraction of ~0.04), however, was ∼10-fold amplified by TSA (Fig. 6) . Moreover, as depicted by Table 1 (14) . It is reasonable to believe that therapeutic indications for these agents primarily will be in combination with conventional cytotoxic therapies.
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